Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
5.17M
-
Number of holders
-
16
-
Total 13F shares, excl. options
-
3.43M
-
Shares change
-
+1.76M
-
Total reported value, excl. options
-
$318K
-
Value change
-
+$159K
-
Number of buys
-
11
-
Number of sells
-
-2
-
Price
-
$0.09
Significant Holders of CERo Therapeutics Holdings, Inc. - Common Stock, $0.0001 par value per share (CERO) as of Q3 2024
18 filings reported holding CERO - CERo Therapeutics Holdings, Inc. - Common Stock, $0.0001 par value per share as of Q3 2024.
CERo Therapeutics Holdings, Inc. - Common Stock, $0.0001 par value per share (CERO) has 16 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3.43M shares
of 5.17M outstanding shares and own 66.26% of the company stock.
Largest 10 shareholders include ARCH Venture Management, LLC (1.44M shares), Avantax Planning Partners, Inc. (1.36M shares), GEODE CAPITAL MANAGEMENT, LLC (157K shares), Selkirk Management LLC (121K shares), HRT FINANCIAL LP (79.6K shares), FIFTH LANE CAPITAL, LP (76.6K shares), JANE STREET GROUP, LLC (57K shares), XTX Topco Ltd (56.5K shares), FNY Investment Advisers, LLC (26.3K shares), and StoneX Group Inc. (16.6K shares).
This table shows the top 16 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.